NASDAQ:HUMA 12 November 2025

Durham, N.C. — November 12, 2025 — Humacyte, Inc. reported third‑quarter results and a pipeline update this morning, highlighting accelerating Symvess™ sales, new clinical data in dialysis access, and a key regulatory step toward first‑in‑human testing of its coronary bypass graft. GlobeNewswire Humacyte posted $753,000 in Q3 revenue—$703,000 from Symvess, the FDA‑approved acellular tissue‑engineered vessel for adult extremity vascular trauma, and ~$100,000 from a collaboration with a large med‑tech partner. Management emphasized a step‑up in VAC approvals and hospital onboarding as the key driver of the sales ramp. GlobeNewswire